Wait...
Search Global Export Import Trade Data
Recent Searches: No Recent Searches

Cadila Healthcare says can ramp up HCQ capacity, vaccine to enter human testing in Q2FY21.


Date: 11-04-2020
Subject: Cadila Healthcare says can ramp up HCQ capacity, vaccine to enter human testing in Q2FY21
Cadila Healthcare, part of Zydus Cadila group said it is ramping up production to meet the demand surge for anti-malaria medicine hydroxychloroquine (HCQ) which is now widely used as a prophalytic drug to prevent COVID-19 infection among healthcare workers and high-risk populations.

"We are currently manufacturing 30 metric tonnes per month which is about 150 million tablets. If need be, we can further increase this to 40 to 50 metric tonnes in the coming months," said Sharvil Patel, Managing Director, Cadila Healthcare to Moneycontrol.

"The priority is to ensure the availability of the drug. We are ramping up our production of hydroxychloroquine. Our efforts are geared towards making sure that all patients who need the drug have access to it," Patel added.

Patel said his company doesn't depend on any imports for the drug, implying that it makes key starting material and intermediates, which are typically imported from China for most other drugs.

Cadila Healthcare and IPCA Laboratories are two big producers globally that are vertically integrated and have USFDA approval to supply the formulation and its active pharmaceutical ingredient.

On shortages of hydroxychloroquine for patients suffering from malaria, rheumatoid arthritis and lupus which the drug is intended for, Patel said, "..might have been a temporary phase, but I think this should be sorted out very soon. With the production being ramped up, the drug should be available to all."

Shares of Cadila Healthcare rose almost 16 percent after India partly lifted the export ban on hydroxychloroquine on April 7 citing "humanitarian" grounds. India produces 70 percent of the world's HCQ requirement.

US President Donald Trump announced stockpiling of 29 million doses (2.9 crore doses) of HCQ as the country grapples with the COVID-19 pandemic. Brazil President Jair Bolsonaro requested India for HCQ. India obliged the request. Several other countries have started enquiring with India about possible supply of the HCQ.

The Indian government too placed an order for 10 crore tablets of HCQ from Cadila Healthcare and IPCA.

Read this explainer to know more about HCQ.

Source:- moneycontrol.com

Get Sample Now

Which service(s) are you interested in?
 Export Data
 Import Data
 Both
 Buyers
 Suppliers
 Both
OR
 Exim Help
+


What is New?

Date: 28-02-2025
Notification No. 12/2025-CUSTOMS (N.T.)
Fixation of Tariff Value of Edible Oils, Brass Scrap, Areca Nut, Gold and Silver- Reg.

Date: 14-02-2025
Notification No. 10/2025-CUSTOMS (N.T.)
Fixation of Tariff Value of Edible Oils, Brass Scrap, Areca Nut, Gold and Silver- Reg.

Date: 13-02-2025
Notification No. 14/2025-Customs
Seeks to amend Notification 11/2021-Customs dated 01.02.2021 to amend AIDC rate on Bourbon whiskey

Date: 11-02-2025
NOTIFICATION No. 09/2025–Central Tax
Seeks to bring rules 2, 8, 24, 27, 32, 37, 38 of the CGST (Amendment) Rules, 2024 in to force

Date: 03-02-2025
[F. No. CBIC-190354/236/2021-TRU]
Corrigendum to Notification No. 50 of 2024 Customs, dated the 30th December, 2024.

Date: 01-02-2025
Notification No. 13/2025-Customs
Seeks to further amend notification No. 153/94-Customs dated the 13 th July, 1994.

Date: 01-02-2025
Notification No. 12/2025-Customs
Seeks to further amend notification No. 19/2019 dated 06 th July 2019.

Date: 01-02-2025
Notification No. 11/2025 – Customs
Seeks to further amend notification No. 25/2002-Customs, dated the 1st March, 2002 so as to add capital goods to the already existing list of capital goods exempted from basic customs duty for manufacture of lithium-ion battery of mobile phones and electrically operated vehicles.

Date: 01-02-2025
Notification No. 09/2025-Customs
Seeks to further amend notification No. 16/2017-Customs, dated the 20 th April, 2017 so to exempt certain drugs for supply under Patient Assistance Programme run by specified pharmaceutical companies.

Date: 01-02-2025
Notification No. 07/2025-Customs
Seeks to further amend notification No. 11/2018-Customs dated 02 th February, 2018 so as to exempt specified goods from the whole of levy of Social Welfare Surcharge.



Exim Guru Copyright © 1999-2025 Exim Guru. All Rights Reserved.
The information presented on the site is believed to be accurate. However, InfodriveIndia takes no legal responsibilities for the validity of the information.
Please read our Terms of Use and Privacy Policy before you use this Export Import Data Directory.

EximGuru.com

C/o InfodriveIndia Pvt Ltd
F-19, Pocket F, Okhla Phase-I
Okhla Industrial Area
New Delhi - 110020, India
Phone : 011 - 40703001